Benitec Biopharma Inc. (NASDAQ:BNTC)’s share price crossed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $3.01 and traded as low as $2.66. Benitec Biopharma shares last traded at $2.72, with a volume of 48,607 shares traded.
The company has a debt-to-equity ratio of 0.05, a current ratio of 10.23 and a quick ratio of 10.23. The firm’s 50 day simple moving average is $2.99 and its two-hundred day simple moving average is $3.53.
Benitec Biopharma (NASDAQ:BNTC) last posted its quarterly earnings results on Monday, November 15th. The biotechnology company reported ($0.62) earnings per share for the quarter. Benitec Biopharma had a negative return on equity of 106.22% and a negative net margin of 23,528.81%.
Several large investors have recently modified their holdings of the company. Geode Capital Management LLC increased its position in shares of Benitec Biopharma by 20.8% during the second quarter. Geode Capital Management LLC now owns 34,493 shares of the biotechnology company’s stock valued at $146,000 after buying an additional 5,933 shares during the period. Northern Trust Corp purchased a new position in shares of Benitec Biopharma during the second quarter valued at about $50,000. State Street Corp purchased a new position in shares of Benitec Biopharma during the second quarter valued at about $89,000. Vanguard Group Inc. increased its position in shares of Benitec Biopharma by 43.3% during the second quarter. Vanguard Group Inc. now owns 74,773 shares of the biotechnology company’s stock valued at $318,000 after buying an additional 22,579 shares during the period. Finally, Renaissance Technologies LLC purchased a new position in shares of Benitec Biopharma during the second quarter valued at about $181,000. 18.62% of the stock is owned by hedge funds and other institutional investors.
Benitec Biopharma Company Profile (NASDAQ:BNTC)
Benitec Biopharma Inc, a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy and chronic hepatitis B virus infection.
Further Reading: Management Fee
Receive News & Ratings for Benitec Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Benitec Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.